文献速递衰弱、肌少症与跌倒多重用药

美国老年人衰弱状态与用药情况:1999-2020年NHANES证据

Frailty Status and Medication Use Among U.S. Older Adults: Evidence From NHANES, 1999-2020.
PubMed 文献 · J Am Geriatr Soc · 2026-10-14

该研究分析美国国家健康与营养调查1999至2020年数据,纳入12,766名≥65岁社区居住老年人,构建衰弱指数并分为强健、轻度衰弱、中重度衰弱三组。结果显示各衰弱组用药数量均随时间增加,且增长幅度与药物类别构成随衰弱状态系统性变化。

要点

  • 各衰弱组用药数量均增加,轻度衰弱者增长幅度最大。
  • 代谢药在所有衰弱组均增加,中枢神经/精神药主要在中重度衰弱组增加。
  • 强健者超多重用药以中枢神经/精神药和外用药为主,衰弱者以心血管和代谢药为主。

核心结论

  • 美国老年人用药二十年间大幅增加,用药数量与构成随衰弱状态系统性变化。

研究设计与样本

  • 基于美国国家健康与营养调查1999年至2020年3月的全国代表性数据,纳入14,962名≥65岁社区居住老年人,其中12,766人数据足以构建衰弱指数。
  • 衰弱分为强健(FI<0.25)、轻度衰弱(FI 0.25-0.34)、中重度衰弱(FI≥0.35),结局为总体及按治疗类别划分的处方药平均数量。

主要发现

  • 1999-2000至2017-2020年,强健者平均用药数从2.0增至2.9(趋势p<0.001),轻度衰弱者从3.9增至5.5(p<0.001),中重度衰弱者从6.0增至7.8(p=0.001)。
  • 心血管药物始终占多重用药最大份额但使用保持稳定,代谢药和中枢神经/精神药驱动用药负担纵向增加。
  • 代谢药在所有衰弱层均增加,中枢神经/精神药主要在中重度衰弱者中增加(p<0.001)。
  • 2017-2020年,超多重用药(≥10种药物)构成随衰弱状态显著不同:强健者以中枢神经/精神药和外用药为主,衰弱者以心血管和代谢药为主。

关键数值与推荐

  • 衰弱指数分类:强健FI<0.25,轻度衰弱FI 0.25-0.34,中重度衰弱FI≥0.35。
  • 超多重用药定义为≥10种药物。

临床怎么用

  • 临床应认识到不同衰弱阶段药物负担的驱动类别不同,轻度衰弱阶段代谢药增长明显,中重度衰弱阶段中枢神经/精神药增长明显。
  • 优化用药时需结合衰弱状态评估药物累积模式,强健者超多重用药需关注中枢神经/精神药和外用药,衰弱者需关注心血管和代谢药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty and polypharmacy commonly coexist among older adults, yet population-level evidence on how the extent and therapeutic composition of medication use evolve across frailty stages remains limited. METHODS: We analyzed nationally representative data from the U.S. National Health and Nutrition Examination Survey spanning 1999 through March 2020. Of 14,962 community-dwelling adults aged ≥ 65 years, 12,766 had sufficient data to construct a frailty index (FI). Frailty was categorized as robust (FI < 0.25), mildly frail (FI 0.25-0.34), or moderate to severely frail (FI ≥ 0.35). Outcomes included the mean number of prescription medications overall and by therapeutic class. Temporal trends were evaluated across frailty groups accounting for the complex survey design. RESULTS: Medication use increased across all frailty groups from 1999-2000 to 2017-2020. The mean number of medications increased from 2.0 to 2.9 among robust individuals (p for trend < 0.001), from 3.9 to 5.5 among mildly frail individuals (p < 0.001), and from 6.0 to 7.8 among those with moderate to severe frailty (p = 0.001). Although cardiovascular agents consistently constituted the largest share of polypharmacy, their use remained stable. In contrast, metabolic and CNS/psychotherapeutic agents drove longitudinal increases in medication burden, with metabolic agents increasing across all frailty strata and CNS/psychotherapeutic agents increasing primarily among adults with moderate to severe frailty (p < 0.001). In 2017-2020, hyperpolypharmacy (≥ 10 medications) composition varied markedly by frailty status. Robust older adults predominantly used CNS/psychotherapeutic and topical agents, whereas frail adults primarily used cardiovascular and metabolic agents. CONCLUSION: Medication use among U.S. older adults increased substantially over two decades, with both the magnitude and composition of medication use pattern varying systematically by frailty status. These findings characterize the population-level landscape of frailty-stratified medication burden and provide clinical context for further research and efforts aimed at optimizing medication use across the frailty spectrum in older adults. Key Points ○ Overall medication use increased over two decades across all frailty strata, but the rate and drivers of increase differed by frailty severity, with the steepest growth observed among mildly frail adults. ○ Metabolic agent use increased more rapidly among mildly frail adults than among robust adults, whereas CNS/psychotherapeutic agent use increased more rapidly among adults with moderate to severe frailty; cardiovascular medication use remained a stable baseline across frailty stages. ○ Hyperpolypharmacy (≥ 10 medications) among robust adults was characterized predominantly by CNS/psychotherapeutic and topical agents, whereas among frail adults it reflected accumulation of cardiometabolic therapies. Why Does This Paper Matter? ○ Different therapeutic classes may contribute to medication burden at different stages of frailty, with metabolic agents driving increases in mild frailty and CNS/psychotherapeutic agents driving increases in moderate‐to‐severe frailty. ○ Recognizing when and how specific drug classes accumulate across the frailty spectrum may inform future efforts to optimize medication use as clinical complexity evolves.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Kim M, Growdon ME, Diaz-Ramirez LG, et al. Frailty Status and Medication Use Among U.S. Older Adults: Evidence From NHANES, 1999-2020. J Am Geriatr Soc. 2026. PMID: 42870717. doi:10.1111/jgs.70759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。